Primary resistance occurs when tumor cells are intrinsically incapable of responding to the immune checkpoint blockade due to defects in antigen presentation, such as the loss of β2-microglobulin or mutations in JAK1/2. The gene discussed is HLA-G; the disease is neoplasm.